Atea Pharmaceuticals, Inc. (AVIR), a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, is on track to report topline results from its phase II combination program in a hepatitis C virus (HCV) trial early this month.
The hepatitis C virus (HCV) causes Hepatitis C, a liver disease that often presents no symptoms, leading many individuals to remain unaware that they have it. If not treated, hepatitis C can result in serious liver damage, such as scarring (cirrhosis) and potentially liver cancer.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.